Deferiprone

From Self-sufficiency
Jump to: navigation, search
Deferiprone
120px
Systematic (IUPAC) name
3-hydroxy-1,2-dimethylpyridin-4(1H)-one
Clinical data
[[Regulation of therapeutic goods |Template:Engvar data]]
Routes of
administration
Oral
Pharmacokinetic data
Metabolism Glucuronidation
Biological half-life 2 to 3 hours
Excretion Renal (75 to 90% in 24 hours)
Identifiers
CAS Number 30652-11-0
ATC code V03AC02 (WHO)
PubChem CID 2972
ChemSpider 2866
Chemical data
Formula C7H9NO2
Molar mass 139.152 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Deferiprone (tradenames include Ferriprox) is an oral drug that chelates iron and is used to treat thalassaemia major.[1]

It is currently licensed for use in Europe and Asia, but not in Canada and the United States.[1]

Controversy

Deferiprone was at the center of a protracted struggle between Nancy Olivieri, a Canadian haematologist and researcher, and the Hospital for Sick Children and pharmaceutical giant Apotex, that started in 1996.[2] Dr. Olivieri's data suggested that deferiprone leads to progressive hepatic fibrosis, a finding which is in dispute.[3][4]

References

  1. 1.0 1.1 Savulescu J (2004). "Thalassaemia major: the murky story of deferiprone". BMJ. 328 (7436): 358–9. doi:10.1136/bmj.328.7436.358. PMC 341373Freely accessible. PMID 14962851.  Full Text.
  2. Viens A, Savulescu J (2004). "Introduction to The Olivieri symposium". J Med Ethics. 30 (1): 1–7. doi:10.1136/jme.2003.006577. PMC 1757126Freely accessible. PMID [http://jme.bmj.com/cgi/content/full/30/1/1 Free Full Text 14872065. [http://jme.bmj.com/cgi/content/full/30/1/1 Free Full Text]] Check |pmid= value (help). 
  3. Brittenham G, Nathan D, Olivieri N, Porter J, Pippard M, Vichinsky E, Weatherall D (2003). "Deferiprone and hepatic fibrosis". Blood. 101 (12): 5089–90; author reply 5090–1. doi:10.1182/blood-2002-10-3173. PMID 12788794.  Full Text.
  4. Wanless I, Sweeney G, Dhillon A, Guido M, Piga A, Galanello R, Gamberini M, Schwartz E, Cohen A (2002). "Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia". Blood. 100 (5): 1566–9. doi:10.1182/blood-2002-01-0306. PMID 12176871.  Full Text.

See also

it:Deferiprone

pl:Deferypron